Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of individualized treatment for hepatitis C patients in the real world.

Journal of gastroenterology and hepatology - 1 Jan 2010

Chen Tsung-Ming, Huang Pi-Teh, Lin Ching-Heng, Tsai Ming-Hung, Lin Lien-Fu, Liu Chung-Cheng, Ho Ka-Sic, Tung Jai-Nien

Abstract excerpt

BACKGROUND AND AIM: Individualized treatment with a combination of peg-interferon and ribavirin for patients with hepatitis C virus (HCV) infection has been validated in randomized controlled clinical trials, but its usefulness in the real world is unknown. The aim of the present study was to ass...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Feasibility Studies
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Precision Medicine

Share to Ribavirin

Share to Taiwan

Source

Identifiers

PMID: 19780879
DOI: 10.1111/j.1440-1746.2009.05946.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19780879-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of individualized treatment for hepatitis C patients in the real world.PMID 19780879Read ↗

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.Semantic proximity Read ↗

Retrospective analysis of hepatitis C infected patients treated through an integrated care model.Semantic proximity Read ↗

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.Semantic proximity Read ↗

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.Semantic proximity Read ↗

Individualization of antiviral treatment regimens for chronic hepatitis C.Semantic proximity Read ↗

Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.Semantic proximity Read ↗

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.Semantic proximity Read ↗

Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.Semantic proximity Read ↗

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.Semantic proximity Read ↗

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Semantic proximity Read ↗

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysisSemantic proximity Read ↗

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.